A photo of Eric Mullins.

Research Director, Hemophilia Treatment Center

Associate Professor, UC Department of Pediatrics



Board Certified

My Biography & Research


As a pediatric hematologist, I specialize in disorders of bleeding and blood clotting. I treat children and adolescents with conditions such as hemophilia, von Willebrand’s disease and disordered menstrual bleeding. I often see patients in the Young Women’s Bleeding Disorder Clinic and the Hemophilia Treatment Center.

I was inspired to pursue my career by my family’s general practitioner, Dr. Cash, who was an exemplary model of how to take care of patients. During medical school at University of Missouri, I was drawn to hematology/oncology because of the science involved in this specialty. I chose pediatrics because I discovered and appreciate that children are much more responsive to following their care plan than adults.

Dr. Bob Janco encouraged my interest in hematology and blood clotting disorders during my residency at Vanderbilt University Medical Center. My fellowship at Cincinnati Children’s Hospital included mentoring by Dr. Ralph Gruppo and Dr. Jay Degen, who pointed me in the direction of my current position.

In addition to treating patients, I perform research. My team and I are examining the impact of blood clotting factors on neurologic disease – diseases of the brain, spinal cord and nerves. We have found that blood clotting plays a key role in the progression of multiple sclerosis, and we hope to find ways to intervene in this disease process.

Clinical Interests

Care of children and adolescents with bleeding and thrombotic disorders; hemophilia; von Willebrand’s disease; Young Women’s Bleeding Disorder Clinic; disordered menstrual bleeding; Hemophilia Treatment Center

Research Interests

Interaction of coagulation factors with immunity and inflammation; inflammatory diseases; multiple sclerosis; sickle cell disease; mouse models of these diseases; coagulation factor knockouts; how hemostatic factors modify the inflammatory response

Academic Affiliation

Associate Professor, UC Department of Pediatrics


Cancer and Blood Diseases, Thrombosis, Hemophilia, Hematology, Cancer and Blood Diseases

My Locations

My Education

MD: University of Missouri, Columbia, MO.

Residency: Vanderbilt University Medical Center, Nashville, TN, 2001-2004.

Fellowship: Pediatric Hematology / Oncology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2004-2007; Pediatric Hemostasis Fellowship, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2007-2008; Chief Fellow, Pediatric Hematology / Oncology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2007-2008.

Board Certifications: Pediatrics, 2004-Present; Pediatric Hematology/Oncology, 2009-Present.

My Publications

Heparin Mimic Material Derived from Cellulose Nanocrystals. Gallagher, ZJ; Fleetwood, S; Kirley, TL; Shaw, MA; Mullins, ES; Ayres, N; Foster, EJ. Biomacromolecules. 2020; 21:1103-1111.

Neuron-generated thrombin induces a protective astrocyte response via protease activated receptors. Rajput, PS; Lamb, J; Kothari, S; Pereira, B; Soetkamp, D; Wang, Y; Tang, J; Van Eyk, JE; Mullins, ES; Lyden, PD. Glia. 2020; 68:246-262.

Plasmin-mediated fibrinolysis enables macrophage migration in a murine model of inflammation. Silva, LM; Lum, AG; Tran, C; Shaw, MW; Gao, Z; Flick, MJ; Moutsopoulos, NM; Bugge, TH; Mullins, ES. Blood. 2019; 134:291-303.

Thrombin Signaling Promotes Pancreatic Adenocarcinoma through PAR-1-Dependent Immune Evasion. Yang, Y; Stange, A; Schweickert, PG; Lanman, NA; Paul, EN; Monia, BP; Revenko, AS; Palumbo, JS; Mullins, ES; Elzey, BD; et al. Cancer Research. 2019; 79:3417-3430.

Hydrogel-coated polyurethane/urea shape memory polymer foams. Dalton, E; Chai, Q; Shaw, MW; McKenzie, TJ; Mullins, ES; Ayres, N. Journal of Polymer Science. Part A, Polymer Chemistry. 2019; 57:1389-1395.

Elimination of the fibrinogen integrin aMb2-binding motif improves renal pathology in mice with sickle cell anemia. Nasimuzzaman, M; Arumugam, PI; Mullins, ES; James, JM; VandenHeuvel, K; Narciso, MG; Shaw, MA; McGraw, S; Aronow, BJ; Malik, P. Blood Advances. 2019; 3:1519-1532.

Phase 1, single-dose escalating study of marzeptacog alfa (activated), a recombinant factor VIIa variant, in patients with severe hemophilia. Gruppo, RA; Malan, D; Kapocsi, J; Nemes, L; Hay, CR M; Boggio, L; Chowdary, P; Tagariello, G; von Drygalski, A; Hua, F; et al. Journal of Thrombosis and Haemostasis. 2018; 16:1984-1993.

Abnormal Uterine Bleeding in Adolescent Women. Mullins, ES; Miller, RJ; Mullins, TL K. Current Pediatrics Reports. 2018; 6:123-131.

Real-world experience with use of Antihemophilic Factor (Recombinant), PEGylated for prophylaxis in severe haemophilia A. Dunn, AL; Ahuja, SP; Mullins, ES. Haemophilia. 2018; 24:e84-e92.

Successful management of concurrent acquired hemophilia A and a lupus anticoagulant in a pediatric hematopoietic stem cell transplant patient. Jones, L; Dandoy, C; Jodele, S; Myers, KC; Luchtman-Jones, L; Quinn, CT; Mullins, E; El-Bietar, J. Bone Marrow Transplantation. 2018; 53:487-489.